Physician profile
Daniel K Bennett
NPI 1376715565
$126,182.68
in general payments reported to CMS, 2019-2025
21 companies · $3,346 in 2025
The $3,346 reported for 2025 was more than what 86% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,774 · 2021: $5,821 · 2022: $31K · 2023: $24K · 2024: $30K · 2025: $3,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $6,382 · Food and Beverage: $4,279 · Travel and Lodging: $3,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,020.00 |
| Consulting Fee | $6,382.00 |
| Food and Beverage | $4,279.40 |
| Travel and Lodging | $3,994.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $115,153.39 | 2019-2025 | Vabysmo |
| Astellas Pharma US INC | $6,761.02 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $1,482.30 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $796.85 | 2019-2025 | Clareon Panoptix Pro, Lensx, Unity |
| Novartis Pharmaceuticals Corporation | $337.41 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $308.62 | 2023-2025 | Syfovre |
| Harrow Eye, LLC | $225.35 | 2025 | Iheezo, Triesence |
| Biogen, INC. | $190.97 | 2022-2024 | Byooviz |
| Eyepoint US, INC. | $145.00 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $139.59 | 2023 | Eylea |
| Glaukos Corporation | $136.92 | 2021 | |
| Abbvie INC. | $131.84 | 2022-2025 | Ozurdex |
| Coopervision INC. | $106.52 | 2024 | Myday Contact Lens |
| Coherus Oncology, INC. | $86.63 | 2023-2024 | |
| Sandoz INC. | $47.01 | 2024 | Cimerli |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $42.85 | 2023 | |
| Allergan, INC. | $30.76 | 2020-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $18.28 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.33 | 2019 | |
| Notal Vision, INC. | $7.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.